A Phase 3 Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalisation.

Trial Profile

A Phase 3 Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalisation.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ADOPT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Nov 2011 Status changed from recruiting to completed.
    • 13 Nov 2011 Results published in the New England Journal of Medicine.
    • 13 Nov 2011 Primary endpoint 'Deep-vein-thrombosis-event-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top